JAK1 and IRS1

Data Source:
HPRD (in vitro, in vivo)

		JAK1	IRS1
Description		Janus kinase 1	insulin receptor substrate 1
Image
GO Annotations	Cellular Component	Nucleus Cytoplasm Endosome Cytosol Cytoskeleton Focal Adhesion Membrane	Nucleus Nucleoplasm Cytoplasm Cytosol Plasma Membrane Insulin Receptor Complex Caveola Intracellular Membrane-bounded Organelle
	Molecular Function	Protein Tyrosine Kinase Activity Non-membrane Spanning Protein Tyrosine Kinase Activity Growth Hormone Receptor Binding Protein Binding ATP Binding Protein Phosphatase Binding Ubiquitin Protein Ligase Binding CCR5 Chemokine Receptor Binding Metal Ion Binding	Phosphotyrosine Residue Binding Transmembrane Receptor Protein Tyrosine Kinase Adaptor Activity Protein Kinase C Binding Insulin Receptor Binding Insulin-like Growth Factor Receptor Binding Protein Binding Signaling Receptor Complex Adaptor Activity SH2 Domain Binding Phosphatidylinositol 3-kinase Binding
	Biological Process	MAPK Cascade Protein Phosphorylation Peptidyl-tyrosine Phosphorylation Cytokine-mediated Signaling Pathway Positive Regulation Of Homotypic Cell-cell Adhesion Intracellular Signal Transduction Interleukin-12-mediated Signaling Pathway Interleukin-15-mediated Signaling Pathway Interleukin-2-mediated Signaling Pathway Interleukin-7-mediated Signaling Pathway Interleukin-9-mediated Signaling Pathway Interleukin-21-mediated Signaling Pathway Response To Antibiotic Interferon-gamma-mediated Signaling Pathway Regulation Of Interferon-gamma-mediated Signaling Pathway Type I Interferon Signaling Pathway Interleukin-6-mediated Signaling Pathway Interleukin-27-mediated Signaling Pathway Interleukin-35-mediated Signaling Pathway Protein Localization To Cell-cell Junction Positive Regulation Of Sprouting Angiogenesis	MAPK Cascade Signal Transduction Positive Regulation Of Cell Population Proliferation Insulin Receptor Signaling Pathway Positive Regulation Of Glucose Metabolic Process Phosphatidylinositol 3-kinase Signaling Positive Regulation Of Fatty Acid Beta-oxidation Response To Insulin Cellular Response To Insulin Stimulus Interleukin-7-mediated Signaling Pathway Glucose Homeostasis Response To Peptide Hormone Positive Regulation Of Phosphatidylinositol 3-kinase Activity Positive Regulation Of Glycogen Biosynthetic Process Positive Regulation Of Glucose Import Negative Regulation Of Insulin Receptor Signaling Pathway Positive Regulation Of Insulin Receptor Signaling Pathway Negative Regulation Of Insulin Secretion Insulin-like Growth Factor Receptor Signaling Pathway Phosphatidylinositol-mediated Signaling Positive Regulation Of Protein Kinase B Signaling Cellular Response To Fatty Acid
Pathways		Interleukin-6 signaling Interleukin-6 signaling MAPK3 (ERK1) activation MAPK1 (ERK2) activation ISG15 antiviral mechanism Interleukin-7 signaling Interleukin-7 signaling Other interleukin signaling RAF/MAP kinase cascade Interleukin-10 signaling Interleukin-4 and Interleukin-13 signaling IL-6-type cytokine receptor ligand interactions Interferon gamma signaling Regulation of IFNG signaling Regulation of IFNG signaling Interleukin-20 family signaling Interleukin-15 signaling Interleukin-15 signaling Interleukin-35 Signalling Interleukin-9 signaling Interleukin-2 signaling Interleukin-12 signaling Interleukin-12 signaling Interleukin-27 signaling Interleukin-27 signaling Interleukin-21 signaling Interferon alpha/beta signaling Interleukin receptor SHC signaling Regulation of IFNA signaling Regulation of IFNA signaling Potential therapeutics for SARS	PI3K Cascade IRS-mediated signalling SOS-mediated signalling SOS-mediated signalling PIP3 activates AKT signaling Interleukin-7 signaling PI3K/AKT activation PI3K/AKT activation Constitutive Signaling by Aberrant PI3K in Cancer IRS-related events triggered by IGF1R Signaling by Leptin RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling IRS activation Signal attenuation Activated NTRK3 signals through PI3K Growth hormone receptor signaling
Drugs		Myricetin 2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one Ruxolitinib Tofacitinib Baricitinib Fostamatinib Fedratinib Filgotinib Upadacitinib Pralsetinib	[4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID
Diseases
GWAS		Autoimmune thyroid disease ( 32581359) Core binding factor acute myeloid leukemia ( 27903959) Eosinophil counts ( 32888494 27863252) Eosinophil percentage of granulocytes ( 27863252) Eosinophil percentage of white cells ( 32888494 27863252) Medication use (thyroid preparations) ( 31015401) Monocyte percentage of white cells ( 32888494) Multiple sclerosis ( 31604244) Neutrophil percentage of granulocytes ( 27863252) Plasma anti-thyroglobulin levels ( 29678681) Platelet count ( 32888494) Plateletcrit ( 32888494) Sum eosinophil basophil counts ( 27863252)	Adiponectin levels ( 22479202 31178129) Adiposity ( 21706003) Apolipoprotein A1 levels ( 32203549) Appendicular lean mass ( 33097823 28724990) Birth weight ( 31043758) BMI (adjusted for smoking behaviour) ( 28443625) BMI in non-smokers ( 28443625) Body fat percentage ( 26833246 28270201) Body mass index (joint analysis main effects and smoking interaction) ( 28443625) Circulating leptin levels or type 2 diabetes ( 32341051) Fasting blood insulin ( 25631608 22581228) Fasting blood insulin (BMI interaction) ( 22581228) Glucose homeostasis traits ( 25524916) HDL cholesterol ( 24097068 25961943 20686565) HDL cholesterol levels ( 32203549 28334899) Heel bone mineral density ( 30598549) High light scatter reticulocyte count ( 32888494) High light scatter reticulocyte percentage of red cells ( 32888494) Immature fraction of reticulocytes ( 32888494) Insulin levels in response to oral glucose tolerance test (fasting) ( 29093273) Lean body mass ( 28724990) Metabolite levels ( 23823483) Modified Stumvoll Insulin Sensitivity Index (model adjusted for BMI) ( 27416945) Problematic alcohol use ( 32451486) Sexual dimorphism in anthropometric traits ( 23754948) Triglyceride levels ( 32203549 28334899) Triglycerides ( 24097068 25961943 20686565) Type 2 diabetes ( 22885922 24509480 29358691 30297969 19734900 31118516 20581827) Visceral adipose tissue/subcutaneous adipose tissue ratio ( 22589738) Waist circumference ( 25673412) Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction) ( 28448500) Waist circumference adjusted for BMI in active individuals ( 28448500) Waist circumference adjusted for body mass index ( 28448500) Waist-hip ratio ( 25673412) Waist-to-hip ratio adjusted for BMI x sex interaction ( 26426971)
Interacting Genes		72 interacting genes: ABL1 AGTR1 BRCA1 BTK CCR1 CCR5 CSF2RB CSF3R CXCR4 EIF2AK2 ELP2 ERBB2 FER FES GAB1 GHR GRB2 H3-4 IFNAR2 IFNGR1 IGF1R IL10RA IL21R IL2RB IL2RG IL3RA IL4R IL5RA IL6ST IL7R IL9R INPP5D INSR IRS1 IRS2 JAK3 JAKMIP1 MDK OSMR PDGFRA PDGFRB PIK3R1 PLA2G4A PLAUR PLCG2 PRKCZ PRMT5 PTK2B PTPN11 PTPN2 PTPN6 PTPRC RACK1 RAF1 SH2B2 SHB SOCS1 SOCS3 STAM STAM2 STAT1 STAT2 STAT3 STAT5A STAT6 SYK TEC TNFRSF1A TOP1 TSHR TYK2 USP6	79 interacting genes: AKT1 ALK AP3S1 APP ATP2A1 ATP2A2 ATP2A3 BCL2L1 BCR CAV1 CDH1 CHUK CRK CSNK2A1 CSNK2B EGFR ERBB2 FBXO25 FBXW8 FER FES FYN GHR GRB10 GRB14 GRB2 IGF1R IKBKB IL4R INSR JAK1 JAK2 JAK3 MAPK1 MAPK3 MAPK8 MAPK9 MTOR NCK2 NEDD4 NPM1 NTRK1 NUMB PASK PDPK1 PELI1 PHIP PIK3R1 PIK3R2 PIK3R3 PLCG2 PRKCD PRKCG PRKCQ PRKCZ PTK2 PTPN1 PTPN11 PTPRC PTPRD PTPRF PTPRU RAD51 ROCK1 RPS6KB1 RPTOR SHC1 SIK2 SOCS1 SOCS3 TRIM72 TUB TYK2 UBC UBTF YWHAB YWHAE YWHAG YWHAZ
Entrez ID		3716	3667
HPRD ID		00992	00943
Ensembl ID		ENSG00000162434	ENSG00000169047
Uniprot IDs		P23458 Q6P669	P35568
PDB IDs		3EYG 3EYH 4E4L 4E4N 4E5W 4EHZ 4EI4 4FK6 4GS0 4I5C 4IVB 4IVC 4IVD 4K6Z 4K77 4L00 4L01 5E1E 5HX8 5IXD 5IXI 5KHW 5KHX 5L04 5WO4 6AAH 6BBU 6C7Y 6DBN 6ELR 6GGH 6HZU 6N77 6N78 6N79 6N7A 6N7B 6N7C 6N7D 6RSB 6RSC 6RSD 6RSE 6RSH 6SM8 6SMB 6TPE 6TPF 6W8L	1IRS 1K3A 1QQG 2Z8C 5U1M 6BNT
Enriched GO Terms of Interacting Partners?
Tagcloud ?
Tagcloud (Difference) ?
Tagcloud (Intersection) ?